

November 29-30, 2018
Amsterdam, NetherlandsAvissar Koren A et al., J Clin Exp Orthop 2018, Volume: 4
DOI: 10.4172/2471-8416-C1-005**LIFE AID COMBO TRIAL – FIBROMYALGIA, MULTIPLE SCLEROSIS & GUILLAIN-BARRÉ****Avissar Koren A¹ and Styr B²**¹Acc Triza Granot Ltd, Israel²The Hebrew University of Jerusalem, Israel

LifeAid Combo is a composition of vitamins and CBD developed for a wide array of autoimmune conditions, covering Guillain-Barré, Multiple Sclerosis, Rheumatoid Arthritis, Crohn, Asthma, Vasculitis and Fibromyalgia. LifeAid Combo is a patient based initiative, created by a patient and tested by the patients via testimonials in the Initial Trial, advised by the expertise of Baruch Styr, Pharmacist, Batya Kornboim, MD, and Igal Yusim Research. All trial participants have consulted with their personal physicians, were informed of the risks and volunteered. After a thorough screening process 320 volunteers qualified for the trial in the Fibromyalgia group, and 255 volunteers qualified for the trial in the Guillain-Barré + MS group. 311 participants finished the trial in the Fibromyalgia group, 248 participants finished the trial in the Guillain-Barré + MS group. No deaths or medical emergencies were found on follow up, all dropouts didn't keep up with the regimen for personal reasons. The participants were given a self-report questionnaire to fill out once a day regarding the effects of the LifeAid Combo for 100 days over five Life Aspects: Appetite, Fatigue, Movement, Pain, Sleep. Effectiveness of the treatment was assessed through Simple Line Regression, over 20% is considered to be effective, under 20% was considered to be not-effective.

Results**Guillain-Barré + MS group**

	Effective
Appetite	68%
Fatigue	41%
Movement	65%
Pain	57%
Sleep	55%

Inflammation flaring up during the trial: 0 episodes

Fibromyalgia group

Effective	
Appetite	68%
Fatigue	37%
Movement	84%
Pain	57%
Sleep	55%

Results Explained

Initial trial results have shown the treatment to have the greatest effect on Appetite, Movement and Pain for the Guillain-Barré + MS group. The overall reduction in inflammation flaring up (0 episodes amongst the Guillain-Barré + MS group during the

trial) appears to be correlated to the an increase in Appetite (68% of participant experienced a significant increase in Appetite during the trial). This increase in Appetite coincides with a reduction in Pain (found to be correlated to increased Appetite) and easier Movement (65% of participant experienced a significant increase in Movement, found to be correlated to reduced inflammation). The treatment was found to be less effective in reducing Fatigue and less effective in improving Sleep quality. Initial trial results have shown the treatment to have the greatest effect on Appetite, Movement and Pain for the Fibromyalgia group. 84% of participant experienced a significant increase in Movement during the trial. This increase in Movement coincides with greater Appetite (correlated to increased Movement) and a reduction in Pain (57% of participant experienced a significant reduction in Pain). The treatment was found to be less effective in reducing Fatigue and less effective in improving Sleep quality.

Biography

Anat Avissar Koren, 36 years old, one of the lucky people with Multiple Sclerosis. My first MS attack happened mid-pregnancy with my daughter Ruth, and put me in a wheelchair. Upon recovering I started looking for a way to walk again. A wheelchair was unacceptable to me. There was nothing I wouldn't do for my baby Ruth. I was looking for information and medicine reviews online and at local communities, but found none. There was no one to explain to me which vitamins will I benefit from, what supplements and life factors are influential alongside the treatment, etc. I started studying and soon came up with the idea for a combo to prevent further attacks. To my surprise, after 2-3 months of trying, it worked. Later, the combo was tried by 1,349 more people in Europe for 3 months with amazing reported results.

founder@lifeaidcombo.com